EMA recommends marketing authorization for donanemab (Kisunla)
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
The 78th World Health Assembly agrees to extend the Global Action Plan on the Public Health Response to Dementia
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
World Alzheimer’s Month 2024 in the Americas Region
ADI is sharing a round-up of the recent activities in the Americas region during this year’s World Alzheimer’s Month. Our member associations in the Americas have showcased their collective strength in the region while making strides in both their dementia awareness-raising efforts as well as their support for those who have been impacted by dementia and their carers.
UK medicines regulator, MHRA approves lecanemab
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
ADI at AAIC 2024
ADI’s Diego Aguilar and Nick House attend the Alzheimer's Association International Conference in Philadelphia (USA), delivering key insights, conducting vital meetings and advocating for care in the era of new treatments.
Lancet Commission identifies two new risk factors for dementia and suggests 45% of cases could be delayed or reduced
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
EMA’s advisory committee (CHMP) recommends not granting marketing authorization for lecanemab
Lecanemab represents the second antibody treatment for Alzheimer’s disease to not be recommended marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Donanemab update: new Alzheimer’s disease treatment approved by the FDA
On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease. Donanemab is the…
ADI Regional Director supporting a National Dementia Plan for Argentina
Regional Director for the Americas, Diego Aguilar, alongside politician and neuroscientist Facundo Manes, and ADI’s Argentinian member association A.L.M.A, joined for urgent action on dementia following steeply increasing dementia forecasts and stalling progress towards a National Dementia Plan in the country.
Asia Pacific Update: ADI director for the region attends international summits
In recent events, ADI Regional Director for Asia-Pacific, DY Suharya, was invited to contribute to key summits, events and meetings, with a key focus on improving dementia care, innovating dementia technology and advising on advocacy across the Asia-Pacific region and beyond.